GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSNW) » Definitions » PB Ratio

NeuroSense Therapeutics (NeuroSense Therapeutics) PB Ratio : (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-07), NeuroSense Therapeutics's share price is $0.185. NeuroSense Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.00. Hence, NeuroSense Therapeutics's PB Ratio of today is .

The historical rank and industry rank for NeuroSense Therapeutics's PB Ratio or its related term are showing as below:

During the past 5 years, NeuroSense Therapeutics's highest PB Ratio was 120.44. The lowest was 0.00. And the median was 0.00.

NRSNW's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.54
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, NeuroSense Therapeutics's average Book Value Per Share Growth Rate was -125.60% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of NeuroSense Therapeutics was 78.40% per year. The lowest was 78.40% per year. And the median was 78.40% per year.

Back to Basics: PB Ratio


NeuroSense Therapeutics PB Ratio Historical Data

The historical data trend for NeuroSense Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics PB Ratio Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - - - -

NeuroSense Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeuroSense Therapeutics's PB Ratio

For the Biotechnology subindustry, NeuroSense Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroSense Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's PB Ratio falls into.



NeuroSense Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

NeuroSense Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.185/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


NeuroSense Therapeutics  (NAS:NRSNW) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


NeuroSense Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Traded in Other Exchanges
Address
11 HaMenofim Street, Building B, Herzliya, ISR, 4676670
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.